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Abstract 
Background: Plasmodium vivax is the second most important human malaria parasite, widely spread across the 
world. This parasite is associated with important issues in the process toward malaria elimination, including potential 
for relapse and increased resistance to chloroquine. Plasmodium vivax multi‑drug resistant (pvmdr1) is suspected to be 
a marker of resistance although definitive evidence is lacking. Progress has been made in knowledge of biological fac‑
tors affecting parasite growth, including mechanisms of regulated cell death and the suspected role of metacaspase. 
Plasmodium vivax metacaspase1 (PvMCA1‑cd) has been described with a catalytic domain composed of histidine 
(H372) and cysteine (C428) residues. The aim of this study was to test for a link between the conserved histidine and 
cysteine residues in PvMCA1‑cd, and the polymorphism of the P. vivax multi‑drug resistant gene (pvmdr1).
Results: Thirty P. vivax isolates were collected from Mauritania, Sudan, and Oman. Among the 28 P. vivax isolates suc‑
cessfully sequenced, only 4 samples showed the conserved His (372)–Cys (428) residues in PvMCA1‑cd. Single nucleo‑
tide polymorphisms observed were H372T (46.4%), H372D (39.3%), and C428R (85.7%). A new polymorphic catalytic 
domain was observed at His (282)–Cys (305) residues. Sequences alignment analysis of pvmdr1 showed SNP in the 
three codons 958, 976 and 1076. A single SNP was identified at the codon M958Y (60%), 2 SNPs were found at the 
position 976: Y976F (13%) and Y976V (57%), and 3 SNPs were identified at the position 1076: F1076L (40%), F1076T 
(53%) and F1076I (3%). Only one isolate was wildtype in all three codons (MYF), 27% were single MYL mutants, and 
10% were double MFL mutants. Three new haplotypes were also identified: the triple mutant YVT was most preva‑
lent (53.3%) distributed in the three countries, while triple YFL and YVI mutants (3%), were only found in samples 
from Sudan and Mauritania.
Conclusions: Triple or quadruple mutants for metacaspase genes and double or triple mutants for Pvmdr1 were 
observed in 24/28 and 19/28 samples. There was no difference in the frequency of mutations between PvMCA1‑
cd and Pvmdr1 (P > 0.2). Histidine and cysteine residues in PvMCA1‑cd are highly polymorphic and linkage 
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Background
Plasmodium vivax has the broadest geographic distribu-
tion worldwide, and is a rising issue outside sub-Saharan 
Africa [1]. According to the World Health Organization 
(WHO), more than a third of the world’s population, 
mostly in Asia and Latin America, is at risk of P. vivax 
malaria infection. In 2013, this parasite was responsible 
for more than one million cases in four countries (Ethio-
pia, India, Indonesia and Pakistan) [2, 3]. Several years 
ago, P. vivax was thought to be absent in sub-Saharan 
Africa based on the fact that this parasite uses the human 
Duffy antigen/chemokine receptor (DARC) to invade red 
blood cells and most African people rarely express this 
receptor. However in the Saharan area, Berber peoples 
(Moors, Tuareg, mostly Duffy-positive blood groups) 
were found infected by P. vivax [4, 5]. The presence of P. 
vivax malaria in Mauritania was reported first in 1948 
[6], and recent studies have shown the predominance of 
P. vivax malaria in Nouakchott, Mauritania [7–10].
In Eastern Africa, cases of P. vivax malaria are mostly 
reported from Ethiopia and Eritrea, reports of P. vivax 
malaria in Sudan are few [11]. However, one of the char-
acteristics of P. vivax infection is the low parasite densities, 
leading researchers to underestimate the real prevalence 
of P. vivax infection in endemic areas. The Sultanate of 
Oman has long been an area of vivax malaria transmis-
sion (33,000 cases in 1990), but was declared free from 
malaria transmission in 2004. However, a focus of local 
transmission was found in September 2007 and second-
ary cases occurred in 2010, in 2011 and in 2012. The local 
cases most probably reflect the high number of migrant 
workers from the Indian subcontinent living and visiting 
their home countries where malaria especially P. vivax is 
endemic. Recently, the Disease Surveillance and Control 
service at the Ministry of Health at Muscat was informed 
of vivax malaria cases in Maabaila in Seeb area, Muscat.
Chloroquine and primaquine have been used to treat P. 
vivax malaria infection for both asexual and liver stages 
[5, 12]. The first reports on chloroquine resistance in P. 
vivax were from Papua New Guinea (PNG) and Indone-
sia in 1989 and 1991, respectively. Subsequently, cases 
of chloroquine resistance have been reported in several 
areas [13–15].
No report yet exists of P. vivax chloroquine resistance 
in Sudan and Mauritania [12, 16], but pvmdr1 muta-
tions are emerging according to observations of imported 
cases from these countries. Several studies have reported 
the link between drug resistance and polymorphisms 
in pvmdr1 gene at codons Y976F and F1076L. Pvmdr1 
mutated codon 976F was linked to treatment failure in 
studies conducted in Southeast Asia and Ethiopia [17, 
18]. However, still no consensus exists regarding the rela-
tionship between polymorphism at codons 976 and 1076 
in the pvmdr1 gene and drug resistance or clinical fail-
ures [19, 20].
Considering the emergence of drug resistance of P. 
vivax and the gaps of knowledge about its biology, stud-
ies of mechanisms of parasite death to seek new drug tar-
gets are much needed. About approximately two decades 
ago, the first evidence of Plasmodium falciparum para-
site apoptosis by DNA fragmentation after drug pres-
sure was reported [21]. Only chloroquine sensitive clones 
were reported to undergo apoptosis, while chloroquine 
resistant clones died by necrosis. These findings opened 
the door to a potential relationship between Plasmo-
dium resistance and apoptosis, suggesting that resistance 
could be associated with default of apoptosis. Apoptosis 
is a regulated cell death, that is central to the develop-
ment and homeostasis in metazoans [22]. Apoptosis was 
thought to be limited to multicellular organisms, but sev-
eral studies have now provided evidence that apoptosis 
occurs in many unicellular organisms [21, 23–27].
Caspases are a family of proteases of cysteine that plays 
a key role in the execution of apoptosis [28]. A caspase-
like family has been identified in plant, fungi and proto-
zoa, and has been named “metacaspases” [29]. In silico 
studies have shown that metacaspases are structurally 
close to caspases and classified in C14 family, clan CD. 
The C14 family is characterized by histidine and cysteine 
residues in the catalytic dyad [29–31].
In the genome of P. falciparum, three metacaspases 
(MCA) were identified (PfMCA1-3), but only PfMCA1 
was shown to possess histidine and cysteine residues 
required for the catalytic activity and to be involved in 
apoptosis of P. falciparum [32]. Likewise, in the P. vivax 
genome, three metacaspases have also been described 
and named PvMC1 (Pv114725), PvMC2 (Pv118575) 
and PvMC3 (Pv08564), respectively. Multiple alignment 
of the predicted caspase domains of the two human 
malaria parasites, P. falciparum (PfMCA1-3) and P. vivax 
(PvMCA1-3) and the murine malaria parasite Plasmo-
dium berghei (PbMCA1-3) has shown that only PfMCA1, 
disequilibrium with SNPs of Pvmdr1 gene may be expected from these three areas with different patterns of P. vivax 
transmission.
Keywords: Plasmodium vivax, Metacaspases, PvMCA1‑cd, pvmdr1 gene, SNP, Drug resistance, Apoptose, Oman, 
Mauritania, Sudan
Page 3 of 10Sow et al. Malar J  (2017) 16:61 
PvMCA1 and PbMCA1 possess the dyad histidine–
cysteine conserved in the catalytic domain [33]. The pro-
teolytic activity of the catalytic domain of PfMCA1 was 
studied in yca1 deficient Saccharomyces cerevisiae, and 
led to growth retardation and a drastic yeast cell death 
[34]. However, little is known about the involvement of 
PvMCA1 expression in the life and death of the P. vivax 
parasite.
Sequence alignment of PVX-114725 (Salvador 1 P. 
vivax metacaspase) with PF13-0289 (P. falciparum met-
acaspase 1) and isolates of P. vivax caspase-like from 
Mauritania (PVMG-03834), Brazil (PVBG-03488), India 
(PVIIG-01002) and North Korea (PVNG-00719) has 
shown a high similarity in the catalytic domain and a con-
served histidine and cysteine residues. The catalytic histi-
dine/cysteine dyad of PfMCA1 is found at positions 404 
and 460 in the coding sequence, while in the PvMCA1-cd 
of P. vivax Sal 1 and P. vivax caspase like-isolates from the 
four endemic countries, these residues are found at posi-
tions 372 and 428. Interestingly, a new putative histidine/
cysteine dyad was identified at positions 282 and 305. The 
objective of the present study was to investigate the rela-
tionship between the polymorphism found in histidine 
and cysteine residues of the catalytic domain of P. vivax 
(PvMCA1-cd) with the putative marker of drug resistance 
pvmdr1 gene in samples collected from three geographi-
cally distant countries (Mauritania, Sudan and Oman).
Methods
Database accession of strains and isolates used in this 
study
Metacaspase sequences typical of distinct endemic areas 
were collected from Genbank: P. vivax metacaspase1 Sal-
vador 1 (Sal-1, Central America, accession PlasmoDB: 
PVX_114725); P. vivax caspase-like Mauritania I (West 
Africa, accession UniprotKB: PVMG-03834), P. vivax 
caspase-like Brazil I (South America, accession Uni-
protKB: PVBG-03488); P. vivax caspase-like India VII 
(Asia, accession UniprotKB: PVIIG-01002) and P. vivax 
caspase-like North Korean (Asia, accession UniprotKB: 
PVNG-00719), and used as references in alignment. P. 
vivax multidrug-resistant gene 1: pvmdr1 (accession: 
GenBank: AY618622) was used for resistance marker 
analysis. Plasmodium falciparum metacaspase1 isolated 
from 3D7 clone (accession: PlasmoDB: PF13-0289) was 
used for comparison.
Blood sample collection
Samples were collected from three malaria endemic or 
non-endemic countries: Mauritania, Sudan and Oman 
(Fig.  1). In Mauritania, the study was conducted in the 
summer period (July to September 2015) in three health 
centers located in Nouakchott: Hôpital Cheikh Zayed, 
Centre Santé de Teyarett and Hôpital Mère-Enfant. 
After informed consent was obtained from all patients 
and/or guardians of children, questionnaires were used 
to record patient information (age, sex, body tempera-
ture, fever, histories of the illness and medical examina-
tion). Blood samples were collected by finger prick and 
were spotted on Whatman® filter papers, and dried and 
stored until use. Thick and thin smears were prepared 
and read by microscopy of Giemsa-stained blood films 
for malaria diagnostic and species of Plasmodium were 
recorded. Among the 20 P. vivax isolates collected dur-
ing this study, 10 were chosen according to their highest 
parasite density. Samples from Sudan were provided by 
the Institute of Endemic Diseases, University of Khar-
toum, Khartoum, Sudan. These samples were collected 
from malaria patients in Whatman filter papers during 
2013–2014. Samples from Oman were obtained from 
slides of Giemsa-stained thick blood film from patients 
of the Indian-subcontinental origin (India, Pakistan and 
Bangladesh) collected in Maabaila in the Seeb area, in 
Muscat, during the same period.
DNA preparation from blood samples
DNA from Mauritania and Sudan samples was extracted 
from blood-spot samples on filter paper with Instagene 
Matrix Resin (Bio-Rad, France), according to the manu-
facturer’s instructions. The identification of species 
was confirmed by real-time PCR using species-specific 
primers [35]. DNA from thick blood films (Oman) was 
extracted as described previously in the literature [36].
PCR amplification of PvMCA1 gene and Pvmdr1 gene
Real-time polymerase chain reaction (PCR) was per-
formed using SYBR Green I dye binding specifically to 
double-stranded DNA. Two pairs primers were used to 
amplify PvMCA1-cd and pvmdr1 Primers were designed 
and synthesized by TIB Molbiol (France). Primers 
sequences and PCR program are presented in Table 1.
Real-time polymerase chain reactions were performed 
in a total volume of 20  µl containing 1  µmol/l of each 
primer, 3  mmol/l MgCl2, and 2  µl of Light Cycler Fast 
Start DNA Master SYBR Green I buffer (Roche Molec-
ular Biochemicals). Five microliters of genomic DNA 
were added to the PCR mixtures. Before sequencing, all 
PCR products were separated on agarose gel (1.5%), and 
expected sizes of PvMCA1-cd and pvmdr1 genes were 
purified using Extraction Kit (Qiagen, France). Sequenc-
ing of PvMCA1-cd and Pvmdr1 genes was carried out by 
the Biofidal Company (Biofidal, France).
Pvcsp genotyping of P. vivax isolates
Extracted DNA was first submitted to PCR for Plas-
modium genus and Plasmodium species detection, as 
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described previously [35]. Oligonucleotide primers and 
PCR conditions are described in Table 1.
All amplification reactions were carried out in a total 
volume of 20 µl and the presence of 250 nM of each oli-
gonucleotide primers for Pvcsp and 2.0 µl of Light Cycler 
Fast Start DNA Master SYBR Green 1 reaction mix. Pri-
mary amplification reactions were initiated with 5.0  µl 
of the template genomic DNA, and 1.0  µl of the prod-
uct of these reactions was used to initiate the secondary 
amplification reactions. The cycling parameters for PCR 
PF13-0289      SDQTLYFSPCNQKKALLIGINYYGTKYELNGCTNDTLRMKDLLVTKYKFYDSSNNIVRLI 365
PVX_114725     SDRILHRSHGNKKKALLIGINYYGSREELSGCTNDTLRMMNLLISKYNFHDSPTSMVRLI 401
PVMG-03834     SDRILHRSHGNKKKALLIGINYYGSREELSGCTNDTLRMMNLLISKYNFHDSPTSMVRLI 333
PVBG-03488    SDRILHRSHGNKKKALLIGINYYGSREELSGCTNDTLRMMNLLISKYNFHDSPTSMVRLI 333
PVIIG-01002    SDRILHRSHGNKKKALLIGINYYGSREELSGCTNDTLRMMNLLISKYNFHDSPTSMVRLI 333
PVNG-00719     SDRILHRSHGNKKKALLIGINYYGSREELSGCTNDTLRMMNLLISKYNFHDSPTSMVRLI 333
* *
PF13-0289      DNEANPNYRPTRRNILSALMWLTRDNKPGDILFFLFSGHGSQEKDHNHIEKDGYNESILP 425
PVX_114725     DNESNPNYRPTRKNILSALNWLTKDNQPGDVFFFLYSGHGSQQKDYTYLEDDGYNETILP 461
PVMG-03834     DNESNPNYRPTRKNILSALNWLTKDNQPGDVFFFLYSGHGSQQKDYTYLEDDGYNETILP 393
PVBG-03488     DNESNPNYRPTRKNILSALNWLTKDNQPGDVFFFLYSGHGSQQKDYTYLEDDGYNETILP 393
PVIIG-01002    DNESNPNYRPTRKNILSALNWLTKDNQPGDVFFFLYSGHGSQQKDYTYLEDDGYNETILP 393
PVNG-00719     DNESNPNYRPTRKNILSALNWLTKDNQPGDVFFFLYSGHGSQQKDYTYLEDDGYNETILP 393
*
PF13-0289      SDFETEGVIIDDELHKYLIQPLNEGVKLIAVVDSCNSGSSIDLAYKYKLKSKKWKEDKNP 485
PVX_114725     CDHKTEGQIIDDELHRFLVQPLNDGVKLIAVMDCCNAGSCIDLAYKYKLKSKKWKEVKNP 521
PVMG-03834     CDHKTEGQIIDDELHRFLVQPLNDGVKLIAVMDCCNAGSCIDLAYKYKLKSKKWKEVKNP 453
PVBG-03488     CDHKTEGQIIDDELHRFLVQPLNDGVKLIAVMDCCNAGSCIDLAYKYKLKSKKWKEVKNP 453
PVIIG-01002    CDHKTEGQIIDDELHRFLVQPLNDGVKLIAVMDCCNAGSCIDLAYKYKLKSKKWKEVKNP 453
PVNG-00719     CDHKTEGQIIDDELHRFLVQPLNDGVKLIAVMDCCNAGSCIDLAYKYKLKSKKWKEVKNP 453
*
PF13-0289      FHVICDVTQFSGCKDKEVSYEVNTGQIAPGGSLVTAMVQILKNNM--------NTPSI 535
PVX_114725     FHVVCDVSQFSGCKDMEFSREIDTGKHAPGGALVTAMIHVLGASEAAQGLPLGVPLNPNA 581
PVMG-03834     FHVVCDVSQFSGCKDMEFSREIDTGRHAPGGALVTAMIHVLGASEAAQGLPLGVPLNPNA 513
PVBG-03488     FHVVCDVSQFSGCKDMEFSREIDTGRHAPGGALVTAMIHVLGASEAAQGLPLGVPLNPNA 513
PVIIG-01002    FHVVCDVSQFSGCKDMEFSREIDTGRHAPGGALVTAMIHVLGASEAAQGLPLGVPLNPNA 513
PVNG-00719     FHVVCDVSQFSGCKDMEFSREIDTGRHAPGGALVTAMIHVLGASEAAQGLPLGVPLNPNA 513
PF13-0289      ITYEYLLHNIHAHVKQHSNQTVTFMSSQKFNMNRLFDFEHIIKNKNNQLGQIINKYIEKN 595
PVX_114725     LTYDHLLQNVSSYIKSYHDQKIVFMASQKFDLDRVFDFDHILRNKNGNLGQNVNKLVQKN 641
PVMG-03834  LTYDHLLQNVSSYIKSYHDQKIVFMASQKFDLDRVFDFDHILRNKNGNLGQNVNKLVQKN 573
PVBG-03488     LTYDHLLQNVSSYIKSYHDQKIVFMASQKFDLDRVFDFDHILRNKNGNLGQNVNKLVQKN 573
PVIIG-01002    LTYDHLLQNVSSYIKSYHDQKIVFMASQKFDLDRVFDFDHILRNKNGNLGQNVNKLVQKN 573
PVNG-00719     LTYDHLLQNVSSYIKSYHDQKIVFMASQKFDLDRVFDFDHILRNKNGNLGQNVNKLVQKN 573
PF13-0289      KSKNKNKLKHELKNLFFF-- 613
PVX_114725     KKTKKSKESKKNKHDFFSFF 661
PVMG-03834     KKTKKSKESKKNKHDFFSFF 593
PVBG-03488     KKTKKSKESKKNKHDFFSFF 593
PVIIG-01002    KKTKKSKESKKNKHDFFSFF 593
PVNG-00719     KKTKKSKESKKNKHDFFSFF 593
Fig. 1 Alignment histidine and cysteine residues in the catalytic domain of metacaspases. The universally conserved histidine (His) and cysteine 
(Cys) residues are marked by a star in the catalytic site. In the PfMCA1 catalytic site, His–Cys are found at position 404 and 460. In the PvMCA1‑cd, 
His–Cys, were identified at position 372 and 428, as well as in P. vivax from Mauritania, Brazil, India and North Korea. A second potential putative 
catalytic site His–Cys was also identified upstream of the catalytic domain at positions 282‑305 in the five P. vivax sequences. Accessions of reference 
strains are PF13‑0289 (ABC84559), PVX‑114725 (EDL46606), PVMG‑03834 (KMZ92479), PVBG‑03488 (KMZ86023), PVIIG‑01002 (KMZ79728), PVNG‑
00719 (KMZ98925)
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were as follows: an initial denaturation step at 95  °C for 
10 min preceded the cycles of annealing at a temperature 
defined for each primer pair (Table 1) for 2 min, exten-
sion step at 72  °C for 2 min, and a denaturation step at 
95 °C for 1 min. After a final annealing step followed by 
5 min of extension, reaction mixtures from each capillary 
were collected and stored at 4 °C until secondary PCR or 
sequencing analysis.
The sequences were determined directly from the 
PCR-purified templates using Qiagen DNA purification 
kit, according to the manufacturer’s instructions. Direct 
sequencing of the full length of pvcsp was performed in 
both directions using a 3730 XL DNA analyzer (Applied 
Biosystems). Sequences were confirmed by BLAST and 
nucleotide sequences were translated into amino acid 
sequences. BioEdit version 7.2.5 was used to analyze 
and control the DNA sequences. MUSCLE (MUltiple 
Sequence Comparison by Log-Expectation) was used 
for sequence alignment. MEGA 7, version 7.0.14, was 
used for phylogenetic analysis. Phylogenetic tree was 
performed using Maximum Likelihood method imple-
mented in MEGA7.
Results
Analysis of pvmdr1 gene polymorphisms
The pvmdr1 gene was successfully sequenced in e 30 P. 
vivax isolates. Sequence analysis of pvmdr1 showed SNPs 
at codons 958, 976 and 1076 (Table 2). Haplotypes with 
a single mutation were identified at the codon position 
M958Y (60%), haplotypes with two mutations were found 
at the position 976: Y976F (13%) and Y976 V (57%) and 
three SNPs were identified at the position 1076: F1076L 
(40%), F1076T (53%) and F1076I (3%). Y976F and F1076I 
mutants were not identified in isolates from Oman. Only 
one isolate showing a wild-type at all three codons (MYF) 
was from Mauritania.
The haplotypes YVT (triple mutant) was the most fre-
quent (16/30, 53.3%), followed by MYL (single mutant) 
(8/30, 26.6%) and both were observed in the three 
countries. The MFL haplotypes (double mutant) were 
observed only in Sudan (3/30, 10%). YFL and YVI were 
only found once in Sudan and in Mauritania, respectively.
Comparison of P. vivax caspase‑like sequences of reference 
strains from different areas
Sequence alignment of P. vivax Sal-1 metacaspase 1 with 
caspase-like sequences of P. vivax isolates from Mau-
ritania I (PVMG-03834), Brazil I (PBG-03488), India 
(PVIIG-01002), North Korea (PVNG-00719) and P. fal-
ciparum metacaspase 1 (PF13-0289) has shown the uni-
versally conserved histidine and cysteine residues in the 
catalytic dyad at the position 372 and 428. Interestingly, 
this analysis revealed a new second putative site of histi-
dine/cysteine catalytic dyad at the position 282 and 305 
(Fig. 1).
Analysis of PvMCA1 catalytic domain
The catalytic domain of metacaspase 1 gene (PvMCA1-
cd) was successfully sequenced in 28 P. vivax isolates. 
Sequences analysis of PvMCA1-cd showed SNPs in the 
catalytic domain (Table  3). Among the 28 P. vivax iso-
lates, only four (one isolate from Mauritania and Oman 
and two from Sudan) showed conserved His (372)–Cys 
(428) residues in the catalytic domain and in the new 
putative site His (282)–Cys (305) (4/28, 14%). The two 
SNPs found in the H372 residue were H372T (13/28, 
46.4%) and H372D (11/28, 39.3%). The only single SNP at 
position C428 was C428R (24/28, 85.7%).
Table 1 Primers used for the amplification of PvMCA1-cd, pvmdr1, and Pvcsp of P. vivax isolates
PvMCA1-cd: catalytic domain of Metacaspase1’s P. vivax
Pvmdr1: multidrug-resistant of P. vivax




Genes Primers Sequences PCR program
PvMCA1‑cd MCA1‑F1 5′‑CATGGAAACAAAAAAAAGG‑3′ 95 °C 10′, 35 cycles 94 °C 30″ 56 °C 30″ 72 °C 2′
MCA1‑R1 5′‑CGAAAACTCCATATCTTTGC‑3′
pvmdr1 mdr1‑F1 5′‑ATAGTCATGCCCCAGGATTG‑3′ 95 °C 10′, 45 cycles 95 °C 10″, 60 °C 10″ and 72 °C 30″
mdr1‑R1 5′‑ACGTTTGGTCTGGACAAGTAT‑3′
Pvcsp VCSP‑OF 5′‑ATGTAGATCTGTCCAAGGCCATAAA‑3′ Primary reaction
VCSP‑OR 5′‑TAATTGAATAATGCTAGGACTAACAATATG‑3′ 95 °C 10′, 40 cycles 95 °C 1′, 58 °C 2′ and 72 °C 2′
VCSP‑NF 5′‑GCAGAACCAAAAAATCCACGTGAAAATAAG‑3′ Nested reaction
VCSP‑NR 5′‑CCAACGGTAGCTCTAACTTTATCTAGGTAT‑3′ 30 cycles 95 °C 1′, 62 °C 2′ and 72 °C 2′
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At the second putative catalytic dyad, the SNPs iden-
tified at H282 and C305 residues were H282K (50%), 
H282M (8%) and C305R (50%), C305T (42%)
Therefore, the distribution of these mutations in the 
three different countries can be shown as following: at 
the 372–428 catalytic site, the TR double mutant was 
predominant (13/28; 31% from Mauritania and Oman 
and 38% from Sudan), followed by DR (11/28; 45% from 
Mauritania, 36% from Oman, 18% from Sudan) and wild 
type HC (4/28; 3% from Mauritania and Oman, 6% from 
Sudan). Thus, wild type and double mutants of the His 
(372)–Cys (428) catalytic dyad were equally distributed 
in the three countries. Similar results were obtained for 
the His (282)–Cys (305) putative catalytic dyad, with sin-
gle and double mutants H282K and C305R/T.
Plasmodium vivax CSP genotyping
Genotyping was successfully performed for Pvcsp. The 
phenotype VK210 was present in all samples with either 
VK210A (GDRADGQPA) or VK210B (GDRAAGQPA).
Discussion
This study is the first to look for a link between Plasmo-
dium apoptosis and drug resistance through comparison 
of polymorphisms in metacaspase 1 gene of P. vivax and 
Pvmdr1 as a marker of resistance. Plasmodium vivax iso-
lates were collected in three endemic and non-endemic 
countries: Mauritania (West Africa), Sudan (northeast-
ern Africa) and Oman (southwestern Asia).
The Nomenclature committee on cell death has 
defined cell death as “accidental” or “regulated” [37] 
to avoid misuse of the terms apoptosis, necrosis or 
autophagy. Accidental cell death is caused by severe 
physical, chemical or mechanical insults. Regulated cell 
death may present both apoptotic and necrotic traits 
that and can be modulated by drugs or genetic interven-
tion [22]. Apoptosis is defined as a caspase dependant 
variant of regulated cell death, triggered by intrinsic or 
extrinsic events. Apoptosis is highly controlled, thus 
reversible, and has been clearly associated with mecha-
nisms of drug resistance in cancer cells. Metacaspases 
are orthologs of caspases recently identified in pro-
tozoan parasites, including the two human malaria 
parasites, P. falciparum and P. vivax. The P. falciparum 
metacaspase 1 protein (PfMCA1) is the most studied 
and its involvement in apoptosis has been demonstrated 
previously [38]. It was demonstrated that cell death 
induced by PfMCA1 is aspartate-dependent protease 
activity. Interestingly, in  vitro chloroquino-resistant 
clone of P. falciparum was reported to lack the aspar-
tates dependent proteolytic activity [34].
Therefore, in this study, the polymorphisms found 
within the PvMCA1-cd gene was compared to the poly-
morphisms of pvmdr1 gene associated with P. vivax drug 
resistance. Samples were collected from three differ-
ent countries with a low suspected rate of documented 
treatment failures, to be able to detect mutations arising 
before fixation.
Analysis of pvmdr1 sequences has shown SNPs at 
three codons 958, 976 and 1076 as previously described 
[6, 12, 15, 17, 19]. The substitution in the codon T958M 
is known as an allelic variant, of which T958 wild-type 
was identified in Ecuador and 958M is thought being 
Table 2 Single nucleotide polymorphisms identified in the 
pvmdr1 gene
Residues that differ from the wild-type P. vivax Sal-I strain are indicated in bold 
type
Nonsynonymous substitutions: Y (Tyrosine), F (Phenylalanine), V (Valine), L 
(Leucine), I (Isoleucine), T (Threonine)
MAURIT Mauritania, ID identification
a GenBank accession no. AY618622 (wild-type strain)
Location/ID‑isolate M958Y Y976F/Y976V F1076L/F1076I/
F1076T
NCBI‑AY618622a M Y F
MAURIT‑61606 M Y F
MAURIT‑00721 M Y L
SUDAN‑KH‑179 M Y L
SUDAN‑KH‑193 M Y L
OMAN‑8 M Y L
OMAN‑39 M Y L
OMAN‑3 M Y L
OMAN‑51 M Y L
OMAN‑48 M Y L
SUDAN‑KH‑144 M F L
SUDAN‑KH‑142 M F L
SUDAN‑KH047 M F L
SUDAN‑KH‑145 Y F L
MAURIT‑06727 Y V I
MAURIT‑Mou15 Y V T
MAURIT‑06826 Y V T
MAURIT‑Chi43 Y V T
MAURIT‑Well30 Y V T
MAURIT‑94241 Y V T
MAURIT‑Jid34 Y V T
MAURIT‑63933 Y V T
SUDAN‑KH‑130 Y V T
SUDAN‑KH‑173 Y V T
SUDAN‑KH‑103 Y V T
SUDAN‑KH‑195 Y V T
OMAN‑52 Y V T
OMAN‑36 Y V T
OMAN‑13 Y V T
OMAN‑17 Y V T
OMAN‑47 Y V T
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characteristic of Asia and Africa [12], while it has also 
been found in samples from Brazil [19]., The allelic form 
958M was identified in samples from Africa and south 
western Asia tested here. Few isolates showed the single 
mutation Y976F (4/30), in agreement with the fact that 
the single 976F mutant is not very common worldwide 
[17, 19]. In contrast, many studies have reported a high 
prevalence of the Y976L and/or F1076L mutants associ-
ated with treatment failure [15, 18]. In Mauritania, muta-
tions at codons Y976F and F1076L in the pvmdr1 gene 
have been reported but no study has established a rela-
tionship between these mutations and clinical responses 
of P. vivax to chloroquine [6].
A high prevalence of double and triple mutants was 
observed in samples from Mauritania, Sudan, and Oman. 
Combined analysis of the three codons showed only one 
isolate from Mauritania with the wild-type MYF. Sin-
gle MYL mutants (27%) were present in the 3 countries, 
while double MFL mutants (10%) were only identified in 
P. vivax isolates from Sudan. These results are in agree-
ment with studies reporting the wildtype MYF in sam-
ples from Nepal, Ecuador, and Sri Lanka, the single MYL 
mutants in samples from Sudan, Nepal, Sri Lanka, Paki-
stan, Amazonas and Brazil. The double MFL mutants 
were mainly reported in Sri Lanka. Furthermore, three 
new nonsynonymous mutations were also identi-
fied (Y976V and F1076I/F1076T), and the triple YVT 
mutants were the most prevalent (53.3%) and distrib-
uted in the three countries while the triple YVI mutants 
(3%) were only found in Mauritania. These unexpected 
Table 3 Single nucleotide polymorphisms found in PvMCA1-cd gene in comparison with pvmdr1 gene
Residues that differ from wild-type P. vivax Sal-1 strain are indicated in bold type
Nonsynonymous substitutions: K (Lysine), M (Methionine), R (Arginine), T (Threonine), D (Acide aspartique)
MAURIT Mauritania, ID identification, ND no-determined
a PVX_114725: PlasmoDB annotation (wild-type strain Sal-1)
Location/ID‑isolate H282M/H282K C305T/C305R H372D/H372T C428R pvmdr1
PlasmoDB‑PVX_114725a H C H C MYF
MAURIT‑00721 H C H C MYL
SUDAN‑KH‑142 H C H C MFL
SUDAN‑KH‑193 H C H C MYL
OMAN‑48 H C H C MYL
MAURIT‑06727 H T D R YVI
MAURIT‑Jid34 H T D R YVT
MAURIT‑63933 H T D R YVT
SUDAN‑KH‑195 H T D R YVT
OMAN‑36 H T D R YVT
OMAN‑13 H T D R YVT
OMAN‑17 H T D R YVT
OMAN‑51 ND T D R MYL
SUDAN‑KH‑103 ND T D R YVT
MAURIT‑94241 M T D R YVT
MAURIT‑Well30 M T D R YVT
MAURIT‑Mou15 K R T R YVT
MAURIT‑06826 K R T R YVT
MAURIT‑61606 K R T R MYF
MAURIT‑Chi43 K R T R YVT
SUDAN‑KH‑179 K R T R MYL
SUDAN‑KH‑144 K R T R MFL
SUDAN‑KH‑145 K R T R YFL
SUDAN‑KH‑130 K R T R YVT
SUDAN‑KH‑173 K R T R YVT
OMAN‑52 K R T R YVT
OMAN‑8 K R T R MYL
OMAN‑39 K R T R MYL
OMAN‑3 K R T R MYL
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mutations were not described previously and their pos-
sible link with drug resistance is unknown.
The results obtained from PvMCA1-cd sequences were 
surprising since only few P. vivax isolates (14%) showed 
the conserved histidine and cysteine residues at position 
372 and 428, while sequence analysis of reference strain P. 
vivax Sal-1 and published strains from Mauritania, Bra-
zil, India and North-Korea showed a conserved catalytic 
dyad. Interestingly, a second potential putative site of 
histidine and cysteine residues was found at position 282 
and 305, in which histidine and cysteine residues were 
also conserved in reference strains. The seven nonsyn-
onymous mutations identified in both sites, and found in 
the three endemic countries, suggested that the catalytic 
domain is variable, in agreement with a study reporting a 
polymorphism in the full-length of P. vivax metacaspase1 
[39].
Phylogenetic tree rooted on P. vivax Sal-1 was built 
using PvMCA1-cd sequences, which showed clearly 
three new taxa, suggesting a divergence occurred 
between the five P. vivax references strains (Salvador, 
Mauritania, Brazil, India, North-Korea) and the isolates 
from Mauritania, Sudan and Oman (Fig. 2). But, the his-
torical occurrence of these polymorphisms in these areas 
remains unknown.
To identify the reviviscence phenotype of this P. vivax 
parasite population circulating in the three countries, 
genotyping was done using the Pvcsp (circumsporozoite 
protein). The circumsporozoite protein gene of P. vivax 
comprises a central repetitive domain flanked by two 
conserved domains [40]. The repetitive domain is com-
posed of a 27  bp element repeated a variable number 
of times. The VK 210 type (type I: GDRADGQPA) and 
the VK 247 type (type II: ANGAGNQPG) are the most 
useful marker for pvcsp genotyping. All our samples dis-
played the VK210 type with different allelic associated 
with sequences repeated from 9 to 17 times. Surprisingly, 
all the isolates showed the VK210 pure genotype, demon-
strating a temperate phenotype. Long latency P. vivax are 
known to be more widespread than generally thought, 
including in North Africa, the Horn of Africa, the Mid-

































































Fig. 2 Molecular phylogenetic analysis by maximum likelihood method rooted on P. vivax Sal‑1. The evolutionary history was inferred by using the 
Maximum Likelihood method based on the Tamura‑Nei model. The tree with the highest log likelihood (−1783.1245) is shown. Initial tree(s) for the 
heuristic search were obtained automatically by applying Neighbor‑Join and BioNJ algorithms to a matrix of pairwise distances estimated using 
the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. The analysis involved 33 
nucleotide sequences. Codon positions included were 1st + 2nd + 3rd + Noncoding. All positions containing gaps and missing data were elimi‑
nated. There were a total of 426 positions in the final dataset. Evolutionary analyses were conducted in MEGA7
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periodicity is of utmost importance to adapt the duration 
of the primaquine regimen for radical cure.
Isolates presenting both quadruple (PvMCA1-cd) and 
triple (Pvmdr1) mutations were observed in Mauritania 
(5/9), in Sudan (3/9) and in Oman (1/9), leading to the 
idea that there is no clear difference in the haplotypes 
from the three areas with the present sample size. While 
the number of samples is too low to draw conclusion, 
there is a trend for more mutation in Mauritania.
Conclusion
The aim of this study was to look for a potential link 
between single nucleotide polymorphisms in the 
PvMCA1-cd and Pvmdr1 genes, in order to test the 
hypothesis of a role for apoptosis or regulated cell death 
in P. vivax drug resistance. Triple or quadruple mutants 
for metacaspase genes and double or triple mutants 
for Pvmdr1 were observed in most samples. There was 
no difference in the frequency of mutations between 
PvMCA1-cd and Pvmdr1 (P  >  0.2). Most of the tri-
ple and quadruple mutants for H/C catalytic dyad were 
also double or triple mutants for Pvmdr1 (18/24, 75%). 
Among the four isolates with the conserved histidine and 
cysteine at both catalytic sites, three were single mutants 
in the pvmdr1gene MYL, and one was double mutant 
MFL. These results showed that mutations in metacas-
pase gene appeared to evolve with a similar frequency 
than Pvmdr1 gene.
The study was based on retrospective analysis of blood 
samples from patients and no information on treat-
ment and follow-up were available. Thus, the exact link 
between apoptosis and drug resistance was not discerni-
ble. However, a trend for both mutants to be associated is 
suspected, which supports the interest for further inves-
tigations to explore the effects of mutations in the histi-
dine and cysteine catalytic dyad of the PvMCA1 protein 
on P. vivax drug resistance.
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